-+ 0.00%
-+ 0.00%
-+ 0.00%

Organogenesis completes FDA BLA submission for ReNu knee osteoarthritis therapy

PUBT·04/28/2026 21:04:39
Listen to the news
Organogenesis completes FDA BLA submission for ReNu knee osteoarthritis therapy
  • Organogenesis completed rolling FDA Biologics License Application submission for ReNu, treatment candidate for symptomatic knee osteoarthritis.
  • Submission started December 2025 with non-clinical modules; clinical modules plus CMC modules now filed.
  • ReNu received FDA RMAT designation for knee osteoarthritis in 2021.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Organogenesis Holdings Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202604281630PRIMZONEFULLFEED9708902) on April 28, 2026, and is solely responsible for the information contained therein.